Compugen Company Profile (NASDAQ:CGEN)

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. View Compugen's Earnings History.

Compugen is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Compugen.

1 analysts have issued twelve-month price targets for Compugen's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Compugen's stock price to reach $14.00 in the next twelve months. View Analyst Ratings for Compugen.

Here are some recent quotes from research analysts about Compugen stock:

• 1. According to Zacks Investment Research, "Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. " (10/3/2017)
• 2. FBR & Co analysts commented, "On February 15, Compugen hosted a conference call to discuss its 4Q16 and FY16 results, and announced that it is searching for a new chairperson for its board of directors to replace its current Chairman Martin Gerstel. We consider the decision benign as Mr. Gerstel’s decision to step down is motivated by his wish to fill the chair with someone who is seasoned in clinical development and commercialization as CGEN draws near to filing its first IND and advancing its own investigational therapy into the clinic. While Mr. Gerstel has successfully led CGEN from using its unique target prediction technologies through discovery of multiple drug targets, we think this decision is logical as CGEN transforms into a clinical-stage company. We look for the first IND filing expected in 4Q17 to be a significant inflection point in the company’s valuation." (2/16/2017)

Some companies that are related to Compugen include Celldex Therapeutics (CLDX), Arbutus Biopharma Corporation (ABUS), Idera Pharmaceuticals (IDRA), Codexis (CDXS), Protagonist Therapeutics (PTGX), Concert Pharmaceuticals (CNCE), Corvus Pharmaceuticals (CRVS), Puretech Health PLC (PRTC), NewLink Genetics Corporation (NLNK), Novavax (NVAX), Curis (CRIS), Horizon Discovery Group PLC (HZD), Nabriva Therapeutics AG (NBRV), Chromadex Corp (CDXC), Merrimack Pharmaceuticals (MACK), Pluristem Therapeutics (PSTI), Advaxis (ADXS) and Silence Therapeutics plc (SLN).

Compugen's management team includes the folowing people:

• Martin S. Gerstel, Chairman of the Board
• Anat Cohen-Dayag Ph.D., President, Chief Executive Officer, Director
• Ari Krashin, Chief Financial Officer
• Zurit Levine Ph.D., Vice President - Research and Discovery
• John Hunter, Vice President - Antibody Research & Development
• Dov Hershberg, Director
• Michal Preminger Ph.D., Director
• Yair Aharonowitz Ph.D., Independent External Director
• Ruth Arnon, Independent Director
• Arie Ovadia, Independent External Director

Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Compugen stock can currently be purchased for approximately $3.85.